BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 12406079)

  • 1. Incidence and nature of CD20-negative relapses following rituximab therapy in aggressive B-cell non-Hodgkin's lymphoma: a retrospective review.
    Kennedy GA; Tey SK; Cobcroft R; Marlton P; Cull G; Grimmett K; Thomson D; Gill D
    Br J Haematol; 2002 Nov; 119(2):412-6. PubMed ID: 12406079
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Histological and immunophenotypic changes in 59 cases of B-cell non-Hodgkin's lymphoma after rituximab therapy.
    Maeshima AM; Taniguchi H; Nomoto J; Maruyama D; Kim SW; Watanabe T; Kobayashi Y; Tobinai K; Matsuno Y
    Cancer Sci; 2009 Jan; 100(1):54-61. PubMed ID: 19038008
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Loss of CD20 expression in relapsed lymphomas after rituximab therapy.
    Haidar JH; Shamseddine A; Salem Z; Mrad YA; Nasr MR; Zaatari G; Bazarbachi A
    Eur J Haematol; 2003 May; 70(5):330-2. PubMed ID: 12694172
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunophenotypic changes and clinical outcome in B-cell lymphomas treated with rituximab.
    Seliem RM; Freeman JK; Steingart RH; Hasserjian RP
    Appl Immunohistochem Mol Morphol; 2006 Mar; 14(1):18-23. PubMed ID: 16540725
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical trials of a mouse-human chimeric anti-CD20 monoclonal antibody (rituximab) for B cell non-Hodgkin's lymphoma in Japan.
    Tobinai K
    Cancer Chemother Pharmacol; 2001 Aug; 48 Suppl 1():S85-90. PubMed ID: 11587374
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The absence of CD20 messenger RNA in recurrent cutaneous B-cell lymphoma following rituximab therapy.
    Rawal YB; Nuovo GJ; Frambach GE; Porcu P; Baiocchi RA; Magro CM
    J Cutan Pathol; 2005 Oct; 32(9):616-21. PubMed ID: 16176299
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment.
    Davis TA; Grillo-López AJ; White CA; McLaughlin P; Czuczman MS; Link BK; Maloney DG; Weaver RL; Rosenberg J; Levy R
    J Clin Oncol; 2000 Sep; 18(17):3135-43. PubMed ID: 10963642
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression.
    Davis TA; Czerwinski DK; Levy R
    Clin Cancer Res; 1999 Mar; 5(3):611-5. PubMed ID: 10100713
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Loss of CD20 antigen expression after rituximab therapy of CD20 positive B cell lymphoma (diffuse large B cell extranodal marginal zone lymphoma combination): a case report and review of the literature.
    Duman BB; Sahin B; Ergin M; Guvenc B
    Med Oncol; 2012 Jun; 29(2):1223-6. PubMed ID: 21805377
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rituximab for aggressive non-Hodgkin's lymphomas relapsing after or refractory to autologous stem cell transplantation.
    Pan D; Moskowitz CH; Zelenetz AD; Straus D; Kewalaramani T; Noy A; Qin J; Teruya-Feldstein J; Portlock CS
    Cancer J; 2002; 8(5):371-6. PubMed ID: 12416894
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD20-negative DLBCL transformation after rituximab treatment in follicular lymphoma: a new case report and review of the literature.
    Alvaro-Naranjo T; Jaén-Martínez J; Gumá-Padró J; Bosch-Príncep R; Salvadó-Usach MT
    Ann Hematol; 2003 Sep; 82(9):585-8. PubMed ID: 12898184
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systemic therapy with cyclophosphamide and anti-CD20 antibody (rituximab) in relapsed primary cutaneous B-cell lymphoma: a report of 7 cases.
    Fierro MT; Savoia P; Quaglino P; Novelli M; Barberis M; Bernengo MG
    J Am Acad Dermatol; 2003 Aug; 49(2):281-7. PubMed ID: 12894078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lymphocyte subsets and viral load in patients with HIV-associated non-Hodgkin's lymphoma treated with anti-CD20 monoclonal antibody and chemotherapy.
    De Paoli P; Vaccher E; Tedeschi R; Caffau C; Zanussi S; Bortolin MT; Crepaldi C; Spina M; Tirelli U
    Cancer Immunol Immunother; 2001 May; 50(3):157-62. PubMed ID: 11419183
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
    Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
    Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-CD20 monoclonal antibody (Rituximab) for therapy of mediastinal CD20-positive large B-cell non-Hodgkin lymphoma with a local tumor extension into the lung of a 10-year-old girl.
    Culić S; Culić V; Armanda V; Kuljis D; Pesutić-Pisac V; Janković S
    Pediatr Hematol Oncol; 2003 Jun; 20(4):339-44. PubMed ID: 12746167
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monoclonal antibody therapy for B-cell lymphoma: clinical trials of an anti-CD20 monoclonal antibody for B-cell lymphoma in Japan.
    Tobinai K
    Int J Hematol; 2002 Dec; 76(5):411-9. PubMed ID: 12512835
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD20-negative relapse of cutaneous B-cell lymphoma after anti-CD20 monoclonal antibody therapy.
    Massengale WT; McBurney E; Gurtler J
    J Am Acad Dermatol; 2002 Mar; 46(3):441-3. PubMed ID: 11862185
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cutaneous B-cell lymphoma with loss of CD20 immunoreactivity after rituximab therapy.
    Clarke LE; Bayerl MG; Ehmann WC; Helm KF
    J Cutan Pathol; 2003 Aug; 30(7):459-62. PubMed ID: 12859745
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunohistochemical CD20-negative change in B-cell non-Hodgkin lymphomas after rituximab-containing therapy.
    Maeshima AM; Taniguchi H; Fujino T; Saito Y; Ito Y; Hatta S; Yuda S; Makita S; Fukuhara S; Munakata W; Suzuki T; Maruyama D; Izutsu K
    Ann Hematol; 2020 Sep; 99(9):2141-2148. PubMed ID: 32451711
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical analysis of rituximab combined with chemotherapy in treating aggressive B-cell non-Hodgkin's lymphoma].
    Zhang HY; Lin TY; Jiang WQ; Zhang L; Huang HQ; Xia ZJ; Sun XF; He YJ; Guan ZZ
    Ai Zheng; 2004 Dec; 23(12):1681-6. PubMed ID: 15601560
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.